Regulation of transcription and tumor suppression by MTG family members
MTG 家族成员对转录和肿瘤抑制的调节
基本信息
- 批准号:9055662
- 负责人:
- 金额:$ 36.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-13 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAddressAffectAtlasesBindingC-terminalCBFA2T1 geneChimeric ProteinsChromatinChromosomal translocationChromosomes, Human, Pair 16Chromosomes, Human, Pair 8Colon CarcinomaComplexDNA Binding DomainDNA MethylationDNA Polymerase IIDataDevelopmentE proteinElongation FactorEnzymesEventFamily memberGene ActivationGene ExpressionGene FamilyGene ProteinsGenesGeneticGenetic TranscriptionGenomeHealthHistonesHodgkin DiseaseLengthLinkMLL geneMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryModelingMusMutateMutationMyelogenousN-terminalNCOR1 geneNCOR2 genePhenotypePhysiologicalPoint MutationProteomicsRNARNA SplicingRUNX1 geneRecruitment ActivityRegulationRoleSolid NeoplasmTAL1 geneTCF3 geneTestingThe Cancer Genome AtlasTranscription ElongationTranscriptional Elongation FactorsTranscriptional RegulationTumor SuppressionVariantWorkYeastsgene repressiongene translocationglobal run on sequencinghistone methyltransferasein vivoinnovationleukemialeukemogenesismalignant breast neoplasmmouse modelmutantnovelnovel strategiesrelease factorresearch studyt(821)(q22q22)transcription factortumortumorigenesisyeast two hybrid system
项目摘要
DESCRIPTION (provided by applicant): Two myeloid translocation gene (MTG) family members, MTG8 and MTG16 are disrupted by chromosomal translocations in acute myeloid leukemia. In addition, the caner genome atlas (TCGA) and other large sequencing studies have identified mutations in MTG family members that are scattered throughout the gene body, suggesting that these may be inactivating mutations. Consistent with this interpretation, MTG16 is affected by DNA methylation in Hodgkin's lymphoma and MTG16 and MTGR1 are under expressed in colon cancer. Our preliminary data support this hypothesis in that inactivating mutations accelerated tumorigenesis in three separate mouse models of cancer. Mechanistically, MTG family members have been tangentially linked to transcriptional control at the level of RNA Pol II pausing and elongation through associations with CDK9 and Tif1 (or "Moonshine"). Our preliminary data shows that MTG family members make direct contacts with key regulators of the transcriptional elongation machinery to negatively regulate gene expression. Importantly, cancer associated mutations of MTG family members affect these contacts with elongation factors. Thus, we hypothesize that MTG-dependent regulation of transcriptional pausing/elongation is a key event in tumor suppression and that release of this negative regulation allows activation of genes controlled by transcriptional pausing. By defining the mechanism by which MTGs regulate transcriptional elongation using genetics and innovative new approaches such as global run on transcription sequencing, and by using mouse models of tumorigenesis, we will directly test this hypothesis and define how loss of transcriptional control at the level of pausing and elongation contributes to tumor development.
描述(由申请人提供):两个髓系易位基因(MTG)家族成员MTG 8和MTG 16在急性髓系白血病中被染色体易位破坏。此外,癌症基因组图谱(TCGA)和其他大型测序研究已经确定了MTG家族成员中分散在整个基因体中的突变,这表明这些突变可能是失活突变。与这种解释一致,MTG 16在霍奇金淋巴瘤中受到DNA甲基化的影响,而MTG 16和MTGR 1在结肠癌中表达不足。我们的初步数据支持这一假设,即失活突变加速了三种不同小鼠癌症模型的肿瘤发生。从机制上讲,MTG家族成员通过与CDK 9和Tif 1(或“月光”)的关联,在RNA Pol II暂停和延长的水平上与转录控制密切相关。我们的初步数据显示,MTG家族成员与转录延伸机制的关键调节因子直接接触,以负调节基因表达。重要的是,MTG家族成员的癌症相关突变影响这些与延伸因子的接触。因此,我们假设,MTG依赖的转录暂停/延长的调节是肿瘤抑制的关键事件,这种负调控的释放允许转录暂停控制的基因的激活。通过使用遗传学和创新的新方法(如转录测序的全局运行)定义MTG调节转录延伸的机制,并通过使用肿瘤发生的小鼠模型,我们将直接测试这一假设,并定义在暂停和延伸水平上转录控制的丧失如何有助于肿瘤的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT W HIEBERT其他文献
SCOTT W HIEBERT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT W HIEBERT', 18)}}的其他基金
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
PRC1 在 RUNX1-ETO 介导的转录控制中的作用
- 批准号:
10445091 - 财政年份:2021
- 资助金额:
$ 36.4万 - 项目类别:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
PRC1 在 RUNX1-ETO 介导的转录控制中的作用
- 批准号:
10298288 - 财政年份:2021
- 资助金额:
$ 36.4万 - 项目类别:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
PRC1 在 RUNX1-ETO 介导的转录控制中的作用
- 批准号:
10652591 - 财政年份:2021
- 资助金额:
$ 36.4万 - 项目类别:
Regulation of transcription and tumor suppression by MTG family members
MTG 家族成员对转录和肿瘤抑制的调节
- 批准号:
8696545 - 财政年份:2014
- 资助金额:
$ 36.4万 - 项目类别:
Regulation of transcription and tumor suppression by MTG family members
MTG 家族成员对转录和肿瘤抑制的调节
- 批准号:
9265416 - 财政年份:2014
- 资助金额:
$ 36.4万 - 项目类别:
FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease
FASEB SRC 关于 HDAC、Sirtuins 以及信号传导和疾病中的可逆乙酰化
- 批准号:
8595760 - 财政年份:2013
- 资助金额:
$ 36.4万 - 项目类别:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
Hdac3 作为 BCL6 依赖性淋巴瘤的治疗靶点
- 批准号:
8607465 - 财政年份:2012
- 资助金额:
$ 36.4万 - 项目类别:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
确定 Hdac3 是 B 细胞淋巴瘤亚型的治疗靶点
- 批准号:
9924498 - 财政年份:2012
- 资助金额:
$ 36.4万 - 项目类别:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
Hdac3 作为 BCL6 依赖性淋巴瘤的治疗靶点
- 批准号:
8230922 - 财政年份:2012
- 资助金额:
$ 36.4万 - 项目类别:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
Hdac3 作为 BCL6 依赖性淋巴瘤的治疗靶点
- 批准号:
8431792 - 财政年份:2012
- 资助金额:
$ 36.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.4万 - 项目类别:
Research Grant